Biotech News
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
investors.mannkindcorp.com2026-05-06 14:54 EST
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced